Recently, the Ministry of Science and Technology, the National Health Commission, CMC Logistical Support Department and the China Food and Drug Administration jointly issued documents approving the nation’s fourth batch of clinical research centers. PUMCH, as the only institution on bulletin in the field of immune diseases, was approved to establish the National Clinical Research Center for Skin and Immune Diseases.
PUMCH, as the originating place of China’s immunity study, has been leading clinical research in this regard. In recent years, to meet the needs of dealing with immune and allergic diseases and supported by state projects, PUMCH has been taking the lead in establishing nationwide immune disease multi-center online coordination platform, China’s main allergic diseases epidemiology platform, and a partners healthcare system; it also established the world’s largest immunity disease databank and sample bank and achieved a series of clinical research results; it played an important role in formulating immunity disease standards, medical student education and the transformation of research findings. In the future, it will continue to give play to the advantage of national innovation base and improve the four-level network (10 regional centers, 100 provincial centers, 1000 city centers and 10000 community clinical research satellite units), carry out strategic study on disease prevention and treatment, research result transformation and application. The establishment of the center will further efforts on clinical study of rheumatology and allergic diseases and therefore contribute to human health care.